Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design.

Autor: Mathias N; Bristol-Myers Squibb, Co., 1 Squibb Dr, New Brunswick, NJ, 08901 USA., Huille S; Sanofi, 13 quai Jules Guesde, 94400 Vitry-Sur-Seine, France. Electronic address: Sylvain.Huille@sanofi.com., Picci M; Novartis Pharma AG, Fabrikstrasse 4, CH-4056 Basel, Switzerland., Mahoney RP; Comera Life Sciences, 12 Gill St, Suite 4650, Woburn, MA 01801 USA., Pettis RJ; Becton-Dickinson, 21 Davis Drive, Research Triangle Park, NC 27513 USA., Case B; KORU Medical Systems, 100 Corporate Dr, Mahwah, NJ 07430 USA., Helk B; Novartis Pharma AG, Werk Klybeck, WKL-681.4.42, CH-4057 Basel, Switzerland., Kang D; Halozyme Therapeutics, Inc., 12390 El Camino Real, San Diego, CA 92130 USA., Shah R; Bristol-Myers Squibb, Co., 1 Squibb Dr, New Brunswick, NJ, 08901 USA., Ma J; Johnson & Johnson Innovative Medicine, 200 Great Valley Pkwy, Malvern, PA 19355 USA., Bhattacharya D; Pfizer, 1 Burtt Road, Building K, Andover MA 01810 USA., Krishnamachari Y; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA., Doucet D; GSK, 1250 South Collegeville Road, Collegeville, PA 19426 USA., Maksimovikj N; Sanofi, 13 quai Jules Guesde, 94400 Vitry-Sur-Seine, France., Babaee S; Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065 USA., Garidel P; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach/Riss, Germany., Esfandiary R; AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878 USA., Gandhi R; Bristol-Myers Squibb, Co., 1 Squibb Dr, New Brunswick, NJ, 08901 USA.
Jazyk: angličtina
Zdroj: Advanced drug delivery reviews [Adv Drug Deliv Rev] 2024 Jun; Vol. 209, pp. 115301. Date of Electronic Publication: 2024 Apr 02.
DOI: 10.1016/j.addr.2024.115301
Abstrakt: Subcutaneous (SC) injections can be associated with local pain and discomfort that is subjective and may affect treatment adherence and overall patient experience. With innovations increasingly focused on finding ways to deliver higher doses and volumes (≥2 mL), there is a need to better understand the multiple intertwined factors that influence pain upon SC injection. As a priority for the SC Drug Development & Delivery Consortium, this manuscript provides a comprehensive review of known attributes from published literature that contribute to pain/discomfort upon SC injection from three perspectives: (1) device and delivery factors that cause physical pain, (2) formulation factors that trigger pain responses, and (3) human factors impacting pain perception. Leveraging the Consortium's collective expertise, we provide an assessment of the comparative and interdependent factors likely to impact SC injection pain. In addition, we offer expert insights and future perspectives to fill identified gaps in knowledge to help advance the development of patient-centric and well tolerated high-dose/high-volume SC drug delivery solutions.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: